10x Genomics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q3 2018 to Q3 2024

Taxonomy & unit: us-gaap: USD
Description: Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary: 10x Genomics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q3 2018 to Q3 2024.
10x Genomics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $33.9M, a 15.7% decline year-over-year.
10x Genomics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $147M, a 12.8% decline year-over-year.
10x Genomics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $167M, a 22% increase from 2022.
10x Genomics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $137M, a 42.6% increase from 2021.
10x Genomics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $96M, a 97.3% increase from 2020.

Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)

Share-based Payment Arrangement, Expense, Quarterly (USD)

Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q3 2024	$147M	$33.9M	-$6.33M	-15.7%	Jul 1, 2024	Sep 30, 2024	10-Q	2024-10-29
Q2 2024	$154M	$38.5M	-$7.2M	-15.8%	Apr 1, 2024	Jun 30, 2024	10-Q	2024-08-08
Q1 2024	$161M	$36.1M	-$5.97M	-14.2%	Jan 1, 2024	Mar 31, 2024	10-Q	2024-04-30
Q4 2023	$167M	$38.9M	-$2.06M	-5.02%	Oct 1, 2023	Dec 31, 2023	10-K	2024-02-15
Q3 2023	$169M	$40.2M	+$6.72M	+20.1%	Jul 1, 2023	Sep 30, 2023	10-Q	2024-10-29
Q2 2023	$162M	$45.7M	+$9.38M	+25.8%	Apr 1, 2023	Jun 30, 2023	10-Q	2024-08-08
Q1 2023	$153M	$42.1M	+$16.1M	+61.6%	Jan 1, 2023	Mar 31, 2023	10-Q	2024-04-30
Q4 2022	$137M	$41M	+$14.1M	+52.3%	Oct 1, 2022	Dec 31, 2022	10-K	2024-02-15
Q3 2022	$123M	$33.5M	+$7.56M	+29.1%	Jul 1, 2022	Sep 30, 2022	10-Q	2023-11-03
Q2 2022	$115M	$36.3M	+$9.38M	+34.8%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-08-04
Q1 2022	$106M	$26M	+$9.87M	+61%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-05-04
Q4 2021	$96M	$26.9M	+$12.6M	+88.5%	Oct 1, 2021	Dec 31, 2021	10-K	2024-02-15
Q3 2021	$83.3M	$26M	+$12.2M	+88.3%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-11-03
Q2 2021	$71.2M	$26.9M	+$13.1M	+94.4%	Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-09
Q1 2021	$58.1M	$16.2M	+$9.46M	+141%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-05-05
Q4 2020	$48.6M	$14.3M	+$9.19M	+181%	Oct 1, 2020	Dec 31, 2020	10-K	2023-02-16
Q3 2020	$39.4M	$13.8M	+$9.91M	+256%	Jul 1, 2020	Sep 30, 2020	10-Q	2021-11-05
Q2 2020	$29.5M	$13.9M	+$10.8M	+358%	Apr 1, 2020	Jun 30, 2020	10-Q	2021-08-06
Q1 2020	$18.7M	$6.72M	+$5.36M	+394%	Jan 1, 2020	Mar 31, 2020	10-Q	2021-05-07
Q4 2019	$13.3M	$5.08M			Oct 1, 2019	Dec 31, 2019	10-K	2022-02-18
Q3 2019		$3.87M	+$3.29M	+558%	Jul 1, 2019	Sep 30, 2019	10-Q	2020-11-12
Q2 2019		$3.03M			Apr 1, 2019	Jun 30, 2019	10-Q	2020-08-12
Q1 2019		$1.36M			Jan 1, 2019	Mar 31, 2019	10-Q	2020-05-12
Q3 2018		$589K			Jul 1, 2018	Sep 30, 2018	10-Q	2019-11-12

* An asterisk sign (*) next to the value indicates that the value is likely invalid.